Firalis Molecular Precision (FMP) is a CAP-accredited, GCLP-compliant multi-omics Contract Research Organization (CRO) delivering high-quality bioanalytical services to pharmaceutical, biotechnology, and academic partners worldwide. With over 15 years of experience and 100+ clients globally, FMP operates at the intersection of precision medicine and translational research, supporting drug discovery, clinical development, and companion diagnostics programs across oncology, neurology, immunology, rare diseases, and cardiovascular disease.

What sets FMP apart is its ability to go beyond data generation. By integrating multimodal molecular data, spanning genomics (NGS, whole exome sequencing, RNA sequencing, DNA methylation sequencing), proteomics (Olink®-certified, immunoassays), and transcriptomics, with clinical context, FMP transforms complex biological information into actionable insights that directly inform drug target discovery, biomarker R&D, mechanism of action studies, target engagement, and clinical trial testing.

FMP’s GCLP-compliant and CAP-accredited infrastructure ensures the regulatory rigor required for biomarker data submitted in support of IND and NDA filings. Its scientific team combines deep omics expertise with a client-first project management approach, providing end-to-end support from study design and sample logistics to data analysis and biomarker interpretation. With a commitment to turnaround excellence, data traceability, and methodological innovation, Firalis Molecular Precision serves as a strategic scientific partner for organizations seeking to accelerate their pipelines and de-risk their clinical programs through molecular precision.